BRAIN Biotech AG · ISIN: DE0005203947 · EQS - Company News

BRAIN Biotech AG Sharpens Focus on Profitable Growth

BRAIN Biotech AG Sharpens Focus on Profitable Growth Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D ratio Significant improvement in the liquidity and earnings situation due to the two completed transactions with Royalty Pharma and Akribion Therapeutics Significant future potential through licensing of furth...

XETR:BNN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News BRAIN Biotech AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (188)
Short Selling (DE) (0)
Short Selling (UK) (0)
12 December 2024 09:00AM
BRAIN Biotech AG Sharpens Focus on Profitable Growth
DE0005203947
BRAIN Biotech AG Sharpens Focus on Profitable Growth Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D ratio Significant improvement in the liquidity and earnings s...
BRAIN Biotech AG
About the publication
31 October 2024 07:20PM
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology
DE0005203947
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees plus additional royalties in exchange for granti...
BRAIN Biotech AG
About the publication
31 October 2024 07:11PM
BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties
DE0005203947
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG signs exclusive pharma licensing ag...
BRAIN Biotech AG
About the publication
03 October 2024 02:00PM
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
DE0005203947
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of the BRAIN Biotech AG that she wishes to resign from her position as an ordinary member of the Superv...
BRAIN Biotech AG
About the publication
20 September 2024 07:50PM
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
DE0005203947
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an investigational compound, deucrictiban...
BRAIN Biotech AG
About the publication
20 September 2024 07:50PM
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
DE0005203947
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech Immediate upfront payment of EUR 18.41 million Royalty monetization of an investigational compound, deucrictiban...
BRAIN Biotech AG
About the publication
20 September 2024 07:47PM
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
DE0005203947
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   BRAIN Biotech AG concludes royalty monetization d...
BRAIN Biotech AG
About the publication
20 September 2024 07:47PM
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
DE0005203947
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.   BRAIN Biotech AG concludes royalty monetization d...
BRAIN Biotech AG
About the publication
29 August 2024 07:30AM
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
DE0005203947
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year Cash on-hand at € 13 million Significantly improved operating cash-flow in the 9M Forecasting a sequentially strong BioProducts quarter in Q4 FY 23/24 August 29, 2024, Zwingenberg/Germany – BRAI...
BRAIN Biotech AG
About the publication
29 May 2024 09:00AM
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
DE0005203947
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes Zwingenberg and Greifswald, May 29, 2024 – BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as Senior Business Development Director Enzymes as of June 1st, 2024. De Vries will continue...
BRAIN Biotech AG
About the publication
28 May 2024 07:30AM
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
DE0005203947
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets  Major milestone payment from pharma-project of € 1.5 million received BioProducts business growth accelerated in Q2, further acceleration expected throughout H2 On-track to meet fiscal year end targets Significantly strengthened cash position Zwing...
BRAIN Biotech AG
About the publication
28 May 2024 07:30AM
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
DE0005203947
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets  Major milestone payment from pharma-project of € 1.5 million received BioProducts business growth accelerated in Q2, further acceleration expected throughout H2 On-track to meet fiscal year end targets Significantly strengthened cash position Zwing...
BRAIN Biotech AG
About the publication
16 April 2024 11:20AM
BRAIN Biotech AG takes next step to optimize group structure
DE0005203947
BRAIN Biotech AG takes next step to optimize group structure BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure. Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG, with the approval of the Supervisory Board, has resolved to merge...
BRAIN Biotech AG
About the publication
14 March 2024 09:00AM
Sustainable drinking pleasure based on agricultural side streams
DE0005203947
Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and Provadis Hochschule jointly develop sustainable, non-alcoholic beverages from agricultural side streams Consortium reaps benefits of new grape varieties adapted to climate change Lif...
BRAIN Biotech AG
About the publication
12 March 2024 05:17PM
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
DE0005203947
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG Face-to-face event at the Zwingenberg site Executive Board and Supervisory Board approved by a clear majority Silent partnership with the State of Hesse approved by a very large majority Zwingenberg, Germany, 12 March 2024 – At today´s Annual General Me...
BRAIN Biotech AG
About the publication
05 March 2024 08:00AM
Protein engineering successfully improves structural proteins for performance materials
DE0005203947
Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials First patent application registered BRAIN Biotech relies on protein engineering expertise and bioinformatics for rational protein design Zwingenberg / Neuried (Germany), March 5, 2024 - BRAIN Biotech AG, leading ...
BRAIN Biotech AG
About the publication
29 February 2024 08:40PM
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
DE0005203947
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives Zwingenberg, Germany, 29 February 2024 – At its meeting today and with the approval of the Supervisory Board, the Management Board of BRAIN Biotech AG has resolved, to issue convertible bonds in the total nominal amount of EUR 5.0 ...
BRAIN Biotech AG
About the publication
29 February 2024 08:06PM
Issuance of EUR 5 million convertible bond with exclusion of subscription rights
DE0005203947
NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. BRAIN Biotech AG: issuance of EUR 5 million converti...
BRAIN Biotech AG
About the publication
28 February 2024 07:30AM
  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24
DE0005203947
3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24 Strong BioScience business in Q1 BioProducts growth to accelerate over the next quarters Optimistic outlook for the business year targeting revenue range of € 58 million to € 62 million Zwingenberg, Germany, 28. February 2024 – BRAIN Biotech AG, a lea...
BRAIN Biotech AG
About the publication
17 January 2024 07:30AM
BRAIN Biotech AG successfully executes growth strategy
DE0005203947
Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy   Group sales grew by 11.8 %, 9.8 % all organic All divisions contribute to growth Successful execution of One-BioProducts strategy Strong progress on BioIncubator pharmaceutical project Deucrictibant Zwingenberg, Germany, 17. January 2024 – BRAIN Biotech AG, a leadi...
BRAIN Biotech AG
About the publication
20 November 2023 09:44AM
Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy
DE0005203947
Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapyZwingenberg, Germany, 20 November, 2023 – The Akribion Genomics team of BRAIN Biotech AG has received the Hessian Founder Award and was also named the winner in its category. The biotech start-up succeeded against a total of 193 applicants from v...
BRAIN Biotech AG
About the publication
28 September 2023 10:30AM
BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competition
DE0005203947
BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competitionZwingenberg (Germany), 28 September 2023 – BRAIN Biotech AG is pleased to announce that its Akribion Genomics team has won the first prize in the “BioRiver Boost! 2023” startup competition for life science founders. The jury awarded the prize for ...
BRAIN Biotech AG
About the publication
14 September 2023 10:30AM
BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®
DE0005203947
BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®Zwingenberg, Germany, 14 September 2023 – BRAIN Biotech AG today announced that the European Patent Office has issued a new patent covering BRAIN’s G-dase E® nucleases as a composition of matter patent. BRAIN Biotech's Akribion Genomic...
BRAIN Biotech AG
About the publication
12 September 2023 03:45PM
Scientist from BRAIN Biotech AG receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease family
DE0005203947
Scientist from BRAIN Biotech AG receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease familyZwingenberg, 12 September 2023 Paul Scholz, scientist at BRAIN Biotech AG, today received the prestigious VAAM Innovation Award 2023 at the annual meeting of the Association for General and Applied Microbiology (VAAM). The bioinformatic...
BRAIN Biotech AG
About the publication
30 August 2023 07:30AM
BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions
DE0005203947
BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions 9M Group topline growth +12.3%, +7.9% organic BioScience 9M growth +12%, all organic OneBioProducts integration in full execution Zwingenberg, Germany, August 30th, 2023 – BRAIN Biotech AG, a leading provider of integrated ...
BRAIN Biotech AG
About the publication
28 June 2023 01:00PM
BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition
DE0005203947
BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition Zwingenberg, Germany, 28 June 2023 – BRAIN Biotech AG is pleased to announce that the Akribion Genomics team has been awarded second place in the Science4Life Venture Cup. The prize was awarded for the team's concept and business plan for their ...
BRAIN Biotech AG
About the publication
28 June 2023 01:00PM
BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition
DE0005203947
BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition Zwingenberg, Germany, 28 June 2023 – BRAIN Biotech AG is pleased to announce that the Akribion Genomics team has been awarded second place in the Science4Life Venture Cup. The prize was awarded for the team's concept and business plan for their ...
BRAIN Biotech AG
About the publication
19 June 2023 12:30PM
Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
DE0005203947
Anniversary of BRAIN Biotech AG: 30 years for a bio-based future Zwingenberg, Germany, June 19, 2023 – BRAIN Biotech, a leading European provider of bio-based products and solutions for industry, celebrates its 30th anniversary. Founded in the 1990s, the company has always been a pioneer in industrial biotechnology, developing innovative solutions...
BRAIN Biotech AG
About the publication
19 June 2023 12:30PM
30 years for a bio-based future
DE0005203947
Anniversary of BRAIN Biotech AG: 30 years for a bio-based future Zwingenberg, Germany, June 19, 2023 – BRAIN Biotech, a leading European provider of bio-based products and solutions for industry, celebrates its 30th anniversary. Founded in the 1990s, the company has always been a pioneer in industrial biotechnology, developing innovative solutions...
BRAIN Biotech AG
About the publication
25 May 2023 07:30AM
BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy
DE0005203947
BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy H1 ‘22/23 growth +16.8%, +8.2% organic Cash position a solid € 9.2 million Full ownership of core asset Biocatalysts Ltd achieved Zwingenberg, Germany, May 25th, 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologi...
BRAIN Biotech AG
About the publication
25 May 2023 07:30AM
BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy
DE0005203947
BRAIN Biotech AG stays on solid growth path with H1 results and accelerates One-BioProducts strategy H1 ‘22/23 growth +16.8%, +8.2% organic Cash position a solid € 9.2 million Full ownership of core asset Biocatalysts Ltd achieved Zwingenberg, Germany, May 25th, 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologi...
BRAIN Biotech AG
About the publication
24 May 2023 09:30AM
BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy
DE0005203947
BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy BRAIN Biotech bought the two remaining minority stakes in Biocatalysts Ltd Transaction financed from existing cash and from new debt All industrial products businesses will now be merged under Biocatalysts’ leadership Zwingenberg (...
BRAIN Biotech AG
About the publication
24 May 2023 09:30AM
BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy
DE0005203947
BRAIN Biotech AG gains full ownership of Biocatalysts Ltd and accelerates execution of its One-BioProducts Strategy BRAIN Biotech bought the two remaining minority stakes in Biocatalysts Ltd Transaction financed from existing cash and from new debt All industrial products businesses will now be merged under Biocatalysts’ leadership Zwingenberg (...
BRAIN Biotech AG
About the publication
08 March 2023 05:20PM
Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG
DE0005203947
Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG Executive Board and Supervisory Board discharged with large majority Large majorities in the re-election of one member to the Supervisory Board and the election of two new members New compensation system for Executive Board approved Zwingenberg (Ge...
BRAIN Biotech AG
About the publication
08 March 2023 05:20PM
Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG
DE0005203947
Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG Executive Board and Supervisory Board discharged with large majority Large majorities in the re-election of one member to the Supervisory Board and the election of two new members New compensation system for Executive Board approved Zwingenberg (Ge...
BRAIN Biotech AG
About the publication
27 February 2023 04:00PM
Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion
DE0005203947
Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion Strategy: building a successful international multi-niche enzyme and food ingredients champion Performance made visible: new organizational setup Incubator: Akribion Genomics to focus on opportunities in therapeutics Upgraded ne...
BRAIN Biotech AG
About the publication
27 February 2023 04:00PM
BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion
DE0005203947
Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion Strategy: building a successful international multi-niche enzyme and food ingredients champion Performance made visible: new organizational setup Incubator: Akribion Genomics to focus on opportunities in therapeutics Upgraded ne...
BRAIN Biotech AG
About the publication
27 February 2023 07:30AM
BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
DE0005203947
BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting Total group revenues plus 35%, organic plus 19% Both segments contribute with double digit organic growth Cash on-hand improved Zwingenberg, Germany, 27. February 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, had a s...
BRAIN Biotech AG
About the publication
27 February 2023 07:30AM
BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting
DE0005203947
BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting Total group revenues plus 35%, organic plus 19% Both segments contribute with double digit organic growth Cash on-hand improved Zwingenberg, Germany, 27. February 2023 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, had a s...
BRAIN Biotech AG
About the publication
22 February 2023 02:00PM
BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment
DE0005203947
BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment Zwingenberg (Germany), 22 February, 2023 – BRAIN Biotech AG, industrial biotechnology and enzyme expert, today announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the R...
BRAIN Biotech AG
About the publication
22 February 2023 02:00PM
BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment
DE0005203947
BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment Zwingenberg (Germany), 22 February, 2023 – BRAIN Biotech AG, industrial biotechnology and enzyme expert, today announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the R...
BRAIN Biotech AG
About the publication
10 February 2023 11:04AM
BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères
DE0005203947
BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères Zwingenberg, Germany February 10th, 2023 BRAIN Biotech AG (“BRAIN”) today announces the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project’s viability and economics of a natur...
BRAIN Biotech AG
About the publication
10 February 2023 11:04AM
BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères
DE0005203947
BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères Zwingenberg, Germany February 10th, 2023 BRAIN Biotech AG (“BRAIN”) today announces the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project’s viability and economics of a natur...
BRAIN Biotech AG
About the publication
16 January 2023 07:30AM
BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment
DE0005203947
BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment Group sales grew by 29% Total operating performance exceeds for the first time 50 million euros Both business segments with strong growth and increasing profitability in the past fiscal year Foundations laid for ongoing future dynamic ...
BRAIN Biotech AG
About the publication
10 January 2023 12:15PM
BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform
DE0005203947
BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform Mode of action suited for applications in oncology Significantly increased addressable market potential Zwingenberg, Germany, 10 January 2023 − BRAIN Biotech AG today announced its intent to prioritize the dev...
BRAIN Biotech AG
About the publication
10 January 2023 12:10PM
prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)
DE0005203947
BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing) Zwingenberg, Germany January 10th, 2023 BRAIN Biotech AG (“BRAIN”) announces that at the Supervisory Board meeting held today, the Executive Management Board of the company with the consent of the Supervisory Board ...
BRAIN Biotech AG
About the publication
09 January 2023 12:10PM
Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site
DE0005203947
Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site Dr. Alexander Pelzer appointed as new Head of Research & Development, BRAIN Biotech Zwingenberg site Dr. Martin Langer takes on additional responsibility as Managing Director BioScience Operations, Zwingenberg Zwingenberg, Germany, 9 January 2023 – Biotechnology and enzyme expe...
BRAIN Biotech AG
About the publication
17 November 2022 10:00AM
BRAIN Biotech AG: MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG
DE0005203947
MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG Block transaction recently successfully closed MP Beteiligungs-GmbH has increased its holding throughout 2022 Long-term supporter of the development of BRAIN Biotech AG Zwingenberg, November 17, 2022 – BRAIN Biotech AG was informed by its anchor investor MP Beteiligungs-GmbH, Kaiserslauter...
BRAIN Biotech AG
About the publication
More BRAIN Biotech AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 188 20th April 2023 Majerus, Dr. Michael DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN